Latest Spago Nanomedical News & Updates

See the latest news and media coverage for Spago Nanomedical. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Spago Nanomedical

Clinical-stage nanomedicines company

spagonanomedical.se
Headquarters
Lund, Sweden
Founded year
2007
Company type
Public company
Number of employees
15–50

Last updated

Latest news about Spago Nanomedical

In short: Spago Nanomedical reached clinical milestones in its Tumorad-01 trial and secured funding through an oversubscribed rights issue.

Company announcements

  • Spago Nanomedical

    Spago Nanomedical reports Q1 2026 financials

    Net sales KSEK 22, loss KSEK -6,798. Strengthens team with new Director CMC. DMC recommends continuing Tumorad-01 trial.

  • Spago Nanomedical

    Spago Nanomedical’s Tumorad-01 study meets primary endpoint

    DMC confirms maximum tolerated dose and recommends two more patients at 15 MBq/kg. Visible tumor uptake observed in head and neck cancer patient.

  • Spago Nanomedical

    Spago Nanomedical continues recruitment in Tumorad-01 study

    The DMC recommends adding two patients at current dose after reviewing safety data from 14 patients, confirming acceptable profile. Visible tumor uptake observed.

  • Spago Nanomedical

    Spago Nanomedical appoints Torsten Malmström as Director CMC & Supply

    He joins the management team to support Tumorad's next clinical phase with extensive CMC experience. The appointment strengthens capabilities for development and commercialization.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Spago Nanomedical

Track Spago Nanomedical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.